Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May;11(2):193-202.
doi: 10.1007/s10048-009-0216-y. Epub 2009 Aug 28.

Increased transcript diversity: novel splicing variants of Machado-Joseph disease gene (ATXN3)

Affiliations

Increased transcript diversity: novel splicing variants of Machado-Joseph disease gene (ATXN3)

Conceição Bettencourt et al. Neurogenetics. 2010 May.

Abstract

Machado-Joseph disease (MJD) is a late-onset neurodegenerative disorder that presents clinical heterogeneity not completely explained by its causative mutation. MJD is caused by an expansion of a CAG tract at exon 10 of the ATXN3 gene (14q32.1), which encodes for ataxin-3. The main goal of this study was to analyze the occurrence of alternative splicing at the ATXN3 gene, by sequencing a total of 415 cDNAs clones (from 20 MJD patients and 14 controls). Two novel exons are described for the ATXN3 gene. Fifty-six alternative splicing variants, generated by four types of splicing events, were observed. From those variants, 50 were not previously described, and 26 were only found in MJD patients samples. Most of the variants (85.7%) present frameshift, which leads to the appearance of premature stop codons. Thirty-seven of the observed variants constitute good targets to nonsense-mediated decay, the remaining are likely to be translated into at least 20 different isoforms. The presence of ataxin-3 domains was assessed, and consequences of domain disruption are discussed. The present study demonstrates high variability in the ATXN3 gene transcripts, providing a basis for further investigation on the contribution of alternative splicing to the MJD pathogenic process, as well as to the larger group of the polyglutamine disorders.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Eur J Biochem. 2004 Aug;271(15):3155-70 - PubMed
    1. Ann Neurol. 1997 Apr;41(4):453-62 - PubMed
    1. Trends Genet. 2004 Feb;20(2):68-71 - PubMed
    1. Gene. 2001 Apr 4;267(1):89-93 - PubMed
    1. Nat Neurosci. 2000 Feb;3(2):157-63 - PubMed

Publication types

LinkOut - more resources